Saniona ejer 50% af Scandion Oncology
-
Burde Saniona ikke ligge højere, med en god pipeline og 50% ejerskab i Scandion Oncology?
Ved godt der er et par emissioner senere på året, men alligevel.
Efter kurseksplosion på 790 pct.: “Personligt tror jeg ikke vi får lov at være i fred”
Danske Scandion Oncology har med mere end en ottedobling af værdien over det seneste år været en af de allerbedste aktier på de svenske børser, og ifølge medstifter og topchef Niels Brünner er der meg
borsen.dk (borsen.dk)
Målet for selskabet er at finde en global partner med resultaterne fra fase 2-forsøget i hånden eller potentielt sælge selskabet, der i dag har Saniona som hovedaktionær med en ejerandel omkring 50 pct.
-
SANIONA RAISES SEK 22 MILLION THROUGH SALES OF SHARES IN SCANDION ONCOLOGY
18:00
PRESS RELEASE22 June, 2020
Saniona (OMX: SANION), a clinical-stage biotech company focused on rare diseases, today announced that it has raised SEK 22 million (USD 2.3 million) through the sale of shares in
Scandion Oncology A/S
(Spotlight Stock Market: SCOL).
Saniona sold 754,577 shares of Scandion Oncology. The sale of shares brings Sanionas ownership stake in Scandion Oncology below 15%. Proceeds will be used to continue Sanionas advancement of mid/late-stage clinical trials with Tesomet in two rare eating disorders: hypothalamic obesity (HO) and Prader Willi Syndrome (PWS), as well as to build its U.S.-based leadership team in support of these programs.
Saniona continues to tighten our focus on building a global, commercial-stage rare disease company, which will require significant capital investment over the next few years said Rami Levin, CEO of Saniona. The 2017 spin-out of our oncology assets into Scandion Oncology has resulted in a win-win situation, creating a highly successful cancer start-up in Scandion Oncology, while allowing Saniona to remain strategically focused on rare diseases, and providing funding for our rare disease programs.
Saniona is preparing to initiate two pivotal clinical trials over the next 12 months, one in hypothalamic obesity and the other in Prader Willi Syndrome. This follows the recent release of the positive top line data from its phase 2 trial in Hypothalamic obesity and the positive FDA interactions on Tesomet in Prader Willi Syndrome.
-
Uanset hvor mange % Saniona ejer i Scandion Oncology, så er det en fin "gratis" ekstra kapital indsprøjtning som Saniona allerede har fået.
Scandion Oncology er steget 800% det sidste år.
-
Utroligt at kursen i Saniona ikke stiger mere på gevinsten ved ejerskabet i Scandion Oncology. Sover svenskerne (Avanza) i timen, da de stadig holder kursen nede? Og kommer der et ordentlig ryk opad, når de "opdager" nyheden? ????
-
Saniona ejer stadig 14% af Scandion Oncology, og med en markedsværdi omkring 1 milliard på Scandion Oncology har Saniona stadig en urealiseret kapital på 140 mill....kunne man forestille sig at Saniona undgår flere emissioner på den baggrund? Hvis ja, så skal kursen meget længere op. Saniona hentede 24 mill ved emissionen d 1/6-20, men nu kan de bare hente pengene ved gevinsten på Scandion Oncology
-
Er markedet endelig ved at vågne op? Utroligt at flere ikke har set den "skjulte" kapital som Saniona har gennem deres ejerskab i Scandion Oncology. Mon ikke 20érne snart er fortid.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind